Rep. Waxman releases three new reports that show (1) Medicare drug plans have raised prices for popular brand-name drugs by more than 4% since January 1; (2) Medicare drug plans now charge 14% more for these drugs than the discredited Medicare drug cards previously charged; and (3) Medicare drug card providers negotiated negligible discounts of at most 3% to 5% from drug manufacturers. One of the three reports was prepared by GAO; it also finds that the Administration had advance warning that its systems would not be able to reconcile enrollment and eligibility data satisfactorily.